Daily adaptive cervical RT maintains target coverage with low observed gastrointestinal toxicity

In 12 cervical cancer patients, online adaptation achieved acceptable target coverage in every adapted fraction, with 8.3% acute grade ≥2 GI toxicity.

KEY POINTS

  • This prospective single-center phase II study evaluated 12 patients with FIGO 2018 stage IB3–IIIC1 cervical cancer receiving definitive chemoradiotherapy with daily online adaptation on a Varian Ethos CBCT-guided linac. Treatment consisted of 45 Gy in 25 fractions to the pelvis, optional nodal SIB to 55 Gy in 25 fractions, and weekly cisplatin 40 mg/m², followed by MRI-guided adaptive brachytherapy.
  • The adaptive workflow omitted the conventional uterine internal target volume expansion, applying a 5-mm isotropic CTV-to-PTV margin instead. Daily CBCT was used to update the uterus, bladder, rectum, bowel and target contours before recalculation and optimization; brachytherapy delivered 4 × 7 Gy to the high-risk CTV, with an overall treatment-time objective of 50 days or less.
  • The trial was designed to enroll 39 patients to investigate a reduction in acute grade ≥2 GI toxicity relative to historical conventional pelvic IMRT data. However, recruitment stopped after 12 treated patients because of workflow and institutional capacity constraints, so the primary endpoint could only be interpreted descriptively. One patient (8.3%) developed acute grade ≥2 GI toxicity, with an exact 95% CI of 0.2–38.5%, and no acute grade ≥3 GI events occurred.
  • Across 300 delivered fractions, an adapted plan was selected in 298 (99.3%). The prescribed target coverage goal of PTV D95% ≥98% was achieved in 89.7% of adapted versus 17.3% of scheduled fractions; using the minimum acceptable D95% ≥95% threshold, compliance was 100% versus 43.7%, illustrating the substantial dosimetric benefit of daily reoptimization.
  • OAR effects were not uniformly favorable. Adaptation improved compliance with selected rectal V30Gy and V40Gy constraints, while some bowel dose-volume parameters increased modestly, generally remaining within protocol limits. The principal measurable advantage was restoration of target coverage with smaller margins rather than consistent reduction in every OAR metric.
  • Mean total treatment-session time was 19 minutes 41 seconds, with a median of 19 minutes 17 seconds. Physician contour review and correction required approximately 5–15 minutes, representing the largest and most variable workflow component; all 12 patients completed treatment, and every patient received at least five cisplatin cycles.
  • At a median follow-up of 32.4 months, all patients were alive, with no local or regional recurrence and no late grade ≥2 GI or GU toxicity. Two-year OS, local failure-free survival and disease-free survival were each estimated at 100% (95% CI 73.5–100%); one distant nodal recurrence developed at 29.4 months, while hematologic toxicity remained substantial, including grade 3–4 lymphopenia in 91.7%.

CLINICAL TAKEAWAY

Daily CBCT-guided adaptation appears feasible for intact-cervix chemoradiotherapy and can preserve target coverage despite omission of conventional ITV margins, with treatment sessions averaging approximately 20 minutes. However, the small, prematurely closed single-arm trial cannot establish reduced clinical toxicity or superior disease control compared with standard IMRT, and larger prospective comparisons are required.

SOURCE

Advances in Radiation Oncology

Browse more research Suggest a correction